ArticleEuropean journal of nuclear medicine and molecular imaging2020
Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2-[
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [European journal of nuclear medicine and molecular imaging · 2021Trial
- Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Assessment of the Type and Degree of Genomic Instability in Gliomas.International journal of molecular sciences · 2026Article
- Metabolic Heterogeneity in High-Grade Glioma Assessed by Multi-Tracer PET and Ex Vivo Metabolomics: A Systematic Review and Meta-Analysis.Metabolites · 2025Review
- Targeting TXN1 Induces G2M Phase Arrest and Apoptosis of Glioma Cells Through P38 MAPK Pathway.Applied biochemistry and biotechnology · 2025Article
- Multiparametric radiomics signature for predicting molecular genotypes in adult-type diffuse gliomas utilizingBMC medical imaging · 2025Article
- Contribution of [Pharmaceuticals (Basel, Switzerland) · 2024Review
- DeepDixon synthetic CT for [Frontiers in neuroscience · 2023Article
- Combination of pre-treatment dynamic [European journal of nuclear medicine and molecular imaging · 2023Article
- Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression.Journal of neuro-oncology · 2022Article
- Two Decades of Brain Tumour Imaging with O-(2-[Cancers · 2022Article
- Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma.Scientific reports · 2022Article
- Automatic detection and delineation of pediatric gliomas on combined [Frontiers in nuclear medicine · 2022Article
- Prognostic value of 11C-methionine volume-based PET parameters in IDH wild type glioblastoma.PloS one · 2022Article
- Dynamic amino-acid PET in neuro-oncology: a prognostic tool becomes essential.European journal of nuclear medicine and molecular imaging · 2021Article
- Prognostic value of pre-irradiation FET PET in patients with not completely resectable IDH-wildtype glioma and minimal or absent contrast enhancement.Scientific reports · 2021Article
- DynamicCancers · 2021Article
- Article
- Use of PET Imaging in Neuro-Oncological Surgery.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeIntegrated histomolecular diagnostics of gliomas according to the World Health Organization (WHO) classification of 2016 has refined diagnostic accuracy and prediction of prognosis. This study aimed at exploring the prognostic value of dynamic O-(2-[
methodsBefore initiation of treatment, dynamic FET PET imaging was performed in patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA). Static FET PET parameters such as maximum and mean tumour/brain ratios (TBR
resultsSixty patients (45 GBM and 15 AA patients) of two university centres were retrospectively identified. Patients with isocitrate dehydrogenase (IDH)-mutant or O
conclusionsOur data suggest that dynamic FET PET allows the identification of patients with longer OS among patients with newly diagnosed IDH-wildtype GBM and AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.